Special Issue "The New Frontier of Therapies for Nuclear Envelope and Lamin-Related Diseases: Selected Papers from 2019 International Meeting on Laminopathies"
Deadline for manuscript submissions: 30 June 2021.
Interests: laminopathies; cell biology of lamins, emerin- and lamin-linked proteins; Emery-Dreifuss muscular dystrophy; Hutchinson–Gilford progeria syndrome (HGPS); mandibuloacral dysplasia; familial partial lipodystrophy type 2
Interests: nuclear lamins; LAP2alpha; nuclear structure; nuclear envelope disassembly and assembly; chromatin organization; cell cycle regulation; premature aging; osteogenesis
Special Issues and Collections in MDPI journals
This Special Issue will consist of selected papers from the 2019 International Meeting on Laminopathies on 2–5 September 2019 in London, UK. This is the 3rd edition of the International Meeting on Laminopathies, which is organized every other year in diverse European countries to gather scientists, clinicians, and patient organizations dealing with lamin research and laminopathies. This event is organized by the Italian Network for Laminopathies and by the French Network for Emery-Dreifuss muscular dystrophy and other nuclear envelope-related diseases. Previous meetings took place in Marseille (France) in 2015 and Bologna (Italy) in 2017. The 2019 edition has been organized as a joint meeting with the UK Nuclear Envelope and Chromatin Organization Meeting, organized by Qiuping Zhang and Kathy Shanahan at King’s College in London in collaboration with Eric Schirmer from the University of Edinburgh. Moreover, a satellite meeting of the European Network for Laminopathies has been scheduled on 3–5 September 2019 to allow cross-fertilization among European researchers, clinicians, patients, and their associations and to foster collaborations. This Special Issue of Cells will be focused on “The New Frontier of Therapies for Nuclear Envelope- and Lamin-Related Diseases”.
In this Special Issue, we aim to highlight approaches that exploit experimental work to identify therapeutic targets and test new therapeutic strategies, which we hope can provide a cure for laminopathies. This Special Issue thus offers the opportunity for attendees of the meeting to contribute and publish research findings and perspectives in this area.
Selected papers from the 2019 International Meeting on Laminopathies reporting on “The New Frontier of Therapies for Nuclear Envelope- and Lamin-Related Diseases” will be considered for publication. The papers submitted and selected for this Special Issue should neither have been previously published nor be under consideration for publication elsewhere and will be subject to a very rigorous peer-review process.
Dr. Giovanna Lattanzi
Dr. Thomas Dechat
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- nuclear envelope
- therapies for laminopathies
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Aggravation of atherosclerosis in Ldlr-KO mice with ubiquitous progerin expression
Authors: Vicente Andrès
Affiliation: Laboratory of Molecular and Genetic Cardiovascular Pathophysiology Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Melchor Fernández Almagro 3, 28029 Madrid (Spain)
Title: Nuclear pore complexes cluster in dysmorphic nuclei of normal and progeria cells during replicative senescence
Authors: Jennifer Röhrl; Karima Djabali
Affiliation: Epigenetics of Aging, Department of Dermatology and Allergy, TUM school of Medicine, Technical University of Munich (TUM), 85748 Garching, Germany.
Title: Heart involvement in laminopathies: an updated overview from pathophysiology to arrhythmic risk stratification and recent advances in clinical management
Authors: Cinzia Forleo 1, Roberta Ruggieri 1, Aldo Agea 1, Sandro Sorrentino 1, Andrea Igoren Guaricci 1, Francesco Loizzi 1, Maria Cristina Carella 1, Miriam Albanese 1, Mara Piccolo 1, Paolo Pollice 1, Bagnu
Affiliation: 1 Cardiology Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy 2 Division of Medical Genetics, Department of Biomedial Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy 3 Interdisciplinary Department of Medicine, Section of Radiology, University of Bari Aldo Moro, Bari, Italy
Abstract: Since 1999 Bonne’s discover of the first mutation in the Lamin A/C gene (LMNA), an increasing number of mutations have been associated with a wide spectrum of human diseases, overall referred to as laminopathies, characterized by large phenotypic heterogeneity, encompassing cardiac, neuromuscular, metabolic disorders and premature aging syndromes. Heart and skeletal muscles are the most affected systems, accounting for about 80% of total LMNA mutations. The cardiac phenotypes of laminopathies are frequently gathered in complex not mutually exclusive clinical patterns and may include electrical disturbances (conduction system defects, supraventricular, and ventricular arrhythmias) and structural abnormalities (mainly left ventricular dysfunction and dilated cardiomyopathy, but also left ventricular non-compaction, arrhythmogenic right ventricular, hypertrophic and, more recently, restrictive cardiomyopathies). The clinical evolution of cardiac laminopathies is variable, representing sudden cardiac death, progression to end-stage heart failure needing heart transplantation, and thromboembolic events the most severe complications. The poor prognosis requires suitable risk stratification. This review aims to explore LMNA-related cardiac phenotypes and to give an update concerning the risk stratification of sudden cardiac death in cardiolaminopathies. We also attempt to summarize LMNA-related altered signaling pathways leading to cardiac laminopathies, and to evaluate current and future therapies in LMNA mutation carriers.